Becton, Dickinson and Company (NYSE:BDX) will issue its quarterly earnings data before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of $2.37 per share for the quarter. Becton, Dickinson and has set its FY17 guidance at $9.42-9.47 EPS.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period in the previous year, the business posted $2.35 earnings per share. The business’s revenue for the quarter was down 5.1% on a year-over-year basis. On average, analysts expect Becton, Dickinson and to post $9.46 EPS for the current fiscal year and $10.45 EPS for the next fiscal year.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 210.97 on Wednesday. The stock has a 50 day moving average of $198.97 and a 200-day moving average of $194.36. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $214.72. The company has a market capitalization of $48.01 billion, a price-to-earnings ratio of 61.10 and a beta of 1.05.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/25/becton-dickinson-and-company-bdx-scheduled-to-post-quarterly-earnings-on-wednesday.html.

A number of equities analysts have issued reports on the stock. Wells Fargo & Company reissued a “positive” rating and set a $235.00 price target (up from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday. They noted that the move was a valuation call. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies reissued a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Bank of America Corporation reissued a “buy” rating and set a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $202.79.

In other news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last quarter, insiders have sold 75,904 shares of company stock worth $15,242,688. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Earnings History for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.